Results 251 to 260 of about 462,488 (300)
Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
Current Pharmaceutical Design, 2020 Background: Concerns of elevated cardiovascular risk with some anti-diabetic medications warrant-ed trials on the cardiovascular outcome to demonstrate cardiovascular safety of newly marketed anti-diabetic drugs.
Gerasimos Siasos +2 more
exaly +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cardiovascular adjustment to antiadrenergic agents
The American Journal of Medicine, 1983A common target organ involvement associated with essential hypertension is left ventricular hypertrophy. A number of, but not all, effective antihypertensive drugs will regress left ventricular hypertrophy. Our attention has focused on the hemodynamic characteristics of those drugs that either directly or indirectly alter sympathetic nervous activity.
B L, Pegram, E D, Frohlich
openaire +2 more sources
Seminars in dialysis, 2011
With a growing population of patients with chronic kidney disease (CKD), it is critical that clinicians are aware of the consequences of how kidney failure affects the pharmacokinetics and pharmacodynamics of cardio- vascular medications. This is particularly true in patients on chronic hemodialysis. Approximately 30% of medication-related prob lems in
Walton, Ted, Thomas, Rebekah
openaire +1 more source
With a growing population of patients with chronic kidney disease (CKD), it is critical that clinicians are aware of the consequences of how kidney failure affects the pharmacokinetics and pharmacodynamics of cardio- vascular medications. This is particularly true in patients on chronic hemodialysis. Approximately 30% of medication-related prob lems in
Walton, Ted, Thomas, Rebekah
openaire +1 more source
Infective Agents and Cardiovascular Disease
Seminars in Vascular Medicine, 2002As a consequence of seminal laboratory and experimental work conducted in the 1970s, infections have recently been recognized among possible risk factors for atherosclerosis and its clinical cardiovascular disease manifestations. The infectious hypothesis also relates to modern atherogenesis theories that consider the crucial role of inflammation in ...
openaire +2 more sources
Therapeutic potential of quercetin as a cardiovascular agent
European Journal of Medicinal Chemistry, 2018Flavonoids are integral components of various vegetation and in foods; consequently, they represent an inevitable part of the diet. Historical and epidemiological proof recommend that diet plans consisting of flavonoids such as quercetin have positive health benefits, especially on the heart.
Rahul V, Patel +5 more
openaire +2 more sources
Antiplatelet agents in cardiovascular disease
Journal of Thrombosis and Thrombolysis, 2011Despite improvements in the treatment of acute coronary syndromes (ACS), cardiovascular disease remains the leading cause of death in the United States. Antiplatelet agents, such as aspirin and clopidogrel, play an important role in the treatment of patients with ACS, particularly those at high risk for whom treatment may yield the greatest benefits ...
openaire +2 more sources
Cardiovascular effects of contrast agents
The American Journal of Cardiology, 1989Iodinated radiologic contrast agents should, ideally, passively provide radiographic contrast in blood vessels and soft tissues but have no effects on physiology, hematology or biochemistry. In practice, no such agent exists although the nonionics most closely approach the ideal.
openaire +2 more sources
Oral antidiabetic agents as cardiovascular drugs
Diabetes, Obesity and Metabolism, 2006The increased risk of cardiovascular disease associated with type 2 diabetes is well documented. Lesser degrees of abnormal glucose metabolism including impaired fasting glycaemia and impaired glucose tolerance are also associated with increased cardiovascular risk.
D P, Macfarlane +2 more
openaire +2 more sources
Cardiovascular Protection with Anti-hyperglycemic Agents
American Journal of Cardiovascular Drugs, 2019Diabetes mellitus is a major risk factor for cardiovascular (CV) disease. Conversely, CV disease is responsible for a majority of the deaths in patients with diabetes. Many drug trials have concentrated on blood glucose (hemoglobin A1c) reduction. This strategy, while reducing microvascular outcomes like nephropathy and neuropathy, has little or no ...
Prakash, Deedwania, Tushar, Acharya
openaire +2 more sources
Oral antiplatelet agents in cardiovascular disease
Vasa, 2019Abstract. Antiplatelet agents significantly reduce mortality and morbidity in ischemic heart disease, cerebrovascular disease and peripheral artery disease (PAD), and are therefore part of guideline-driven daily medical treatment in these patients. Due to its beneficial effects in the secondary prevention of atherothrombotic events, aspirin remains ...
Joseph, Pultar +3 more
openaire +2 more sources